Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3596 - Evaluation of an interactive electronic patient reported outcome (e-PRO) system in outpatient with oral chemotherapy


09 Oct 2016


Poster display


Marika Rasschaert


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


M. Rasschaert1, K. Papadimitriou2, S. Altintas2, M. Huizing2, J. Van den Brande2, T. Van den Mooter2, P.M.C. Specenier3, C.D. Rolfo1, S. De Keersmaecker2, I. Van Brussel4, J. Ravelingien5, M. Peeters1

Author affiliations

  • 1 Moca, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 2 Moca, U.Z.A. University Hospital Antwerp, Edegem/BE
  • 3 Medical Oncology, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 4 Project Manager, Remedus, Aartselaar/BE
  • 5 Management, Remedus, Aartselaar/BE


Abstract 3596


Health Information Technology (HIT) is increasingly integrated in clinical cancer care. Simultaneously routine assessment of patient reported outcomes (PROs) has been shown to reliably improve symptom management, identification of psychosocial problems and patient-provider communication.


This study is a single center experience of a multicenter randomized study for the development and validation of an interactive e-PRO tool (RemeCoach). After obtaining informed consent, outpatients, using oral anti-cancer treatment, recorded their medication intake and 17 clinical parameters using this E-PRO tool. The device allowed real time data collection and communication with other care providers via a central platform. The registered data were processed by an algorithm, this algorithm stratifies the data into different grades according to international standards of care (CTCAE v4.0) and clinical importance. Patient clinical and demographic information is collected from medical records and analyzed using descriptive statistics.


37 Patients were included, 59% male, mean age 59,2 (range 38-79). 35% Of patients used capecitabine, 43% regorafenib, 5% pazopanib, 5% everolimus and 5% sunitinib. Most common symptoms cited were fatigue, cutaneous toxicity, myalgia and joint pain and cough. Out of 19 patients that stopped therapy, one (5%) dropped out of the study, 1 switched therapy due to progressive disease, 8 (42%) patients died, 9 (48%) terminated prescribed treatment. The RemeCoach was well adopted: > 75% patients registered > 75% of clinical outcomes.


This study confirms the feasibility of the program, in an outpatient setting. This e-tool provides a means to register compliance, early symptoms of disease and toxicity of treatment.The compliance to the e-PRO tool will be confirmed, with further development of this program in a multicenter, randomized design. Evaluation of quality of life PRO-measurements and further exploration of the relationship between optimal pharmacovigilance and improvement of patient's outcome will ensue.

Clinical trial identification

Legal entity responsible for the study

University Hospital Antwerp


University Hospital Antwerp


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings